Improve Effectiveness of Cardiac Assessments in Early Phase Trials with Early Precision QT and AI-powered Data Quality Checks Webinar Replay
Early and accurate Phase I data is crucial to maintaining safety and determining the viability of new drug entities. Cardiac safety assessments, particularly those focused on the QT interval, play a key role in assessing potential toxicity and guiding portfolio decisions. Therefore, accurately evaluating cardiac safety earlier in the development process may save time, resources and costly future studies.
In this on demand webinar, you will gain insight into:
- The advantages of leveraging EPQT and AI-powered data quality in early phase QT assessment
- Considerations for determining whether early phase QT data may support regulatory waiver of a stand-alone QT study
- How automatic, AI-enabled ECG quality assessments can provide timely feedback on the overall quality of the data and can help reduce the risk of missing or inaccurate data that is essential for obtaining a QT waiver
